Haemonetics (HAE) Q1 2027 earnings review
IVT Rebounds and Guidance Raised, but Margins Compress
Haemonetics delivered a solid start to FY27, prompting a raise in full-year organic revenue guidance to 4-7%. The most significant positive development was the long-awaited reversal in Interventional Technologies (IVT), which grew 2.5% after four consecutive quarters of steep declines. However, this top-line success was overshadowed by profitability headwinds. Adjusted operating margin compressed by 70 basis points to 23.4%, driven by difficult software revenue comps and escalating freight and personnel costs. This creates an uphill battle to achieve the company's reaffirmed full-year guidance of 50-100 bps margin expansion.
🐂 Bull Case
After a grueling FY26 where IVT was a persistent drag (declining 5-12% per quarter), the segment successfully reversed into positive territory (+2.5% YoY). This validates management's prior assertion that Q4 was the inflection point.
Free cash flow accelerated dramatically to $39.1M from just $2.5M in the prior year quarter, driven by favorable working capital adjustments and lower non-cash inventory transfers.
🐻 Bear Case
Adjusted operating margin fell 70 bps to 23.4%. To achieve the reaffirmed FY27 guidance of 50-100 bps expansion, the company will need substantial margin acceleration in the remaining three quarters.
Adjusted operating expenses grew 6.7% YoY, outpacing the 5.9% organic revenue growth. Persistent macro pressures from freight charges and higher personnel costs are pressuring profitability.
⚖️ Verdict: ⚪
Neutral/Slightly Bullish. The return to growth for IVT is a major derisking event for the stock and justifies the revenue guidance raise. However, the margin compression and rising OpEx demand caution until the company proves it can expand margins in the back half of the year.
Key Themes
Interventional Technologies (IVT) Inflection
Reversing. The IVT segment grew 2.5% on a reported basis (2.8% organic) to $59.9M. This marks a critical break in trend from the heavy declines seen throughout FY26 (caused by PFA adoption impacts on esophageal cooling and competitive pressure in vascular closure). The turnaround efforts, including the VASCADE MVP XL label expansion and revamped commercial team, appear to be gaining traction.
Blood Management Continues to Deliver
Stable. Blood Management Technologies (BMT) delivered $88.1M in revenue, growing 8.6% reported (8.1% organic). The sustained momentum in Hemostasis Management (TEG) and ongoing global adoption of the HN cartridge continue to act as reliable growth engines for the MedSurg business.
Plasma Franchise Outpacing Market
Stable. Plasma revenue increased 7.2% to $155.5M (8.2% organic). Growth is primarily being driven by share gains and the rollout of the NexSys platform with Persona Plus, which provides a 5% yield enhancement, creating strong customer stickiness and pricing power.
Operating Margin Compression Contradicts Guidance
Reversing. Despite guiding for 50-100 bps of full-year adjusted operating margin expansion, Q1 margins went in the opposite direction, declining 70 bps to 23.4%. Management attributed this to difficult prior-year comps (which included an upfront software revenue recognition event) as well as increased personnel and freight costs. This leaves a steep hill to climb for the rest of FY27.
Macro Pressures on Operating Expenses
Accelerating. Adjusted operating expenses increased by $7.9M (6.7%) to $125.6M. The growth rate of OpEx outpaced organic revenue growth (5.9%), displaying negative operating leverage. The company specifically cited higher freight charges as a macro pressure, alongside personnel costs.
Elevated Tax Rate Pressures EPS
Accelerating. The effective tax rate jumped significantly from 24.7% in Q1 FY26 to 30.6% in Q1 FY27 (Adjusted tax rate rose 180 bps to 25.7%). This increase was driven by stock compensation shortfalls and valuation allowance impacts related to losses in recently acquired jurisdictions, effectively muting bottom-line EPS growth despite top-line revenue beats.
Other KPIs
Accelerating. A massive improvement compared to the $2.5M generated in Q1 of the prior year. This was primarily driven by favorable working capital adjustments (timing of receivables collections) and lower non-cash transfers from Haemonetics equipment, partially offset by slightly higher capital expenditures.
Stable. Up 5.3% reported. Note that Haemonetics updated its financial reporting taxonomy, grouping Plasma ($155.5M) and Other Blood Collection devices ($35.8M) into the consolidated 'Apheresis' banner. The 'Other' category remains a drag, declining 2.4% YoY.
Guidance
Accelerating. Raised from previous guidance of 4% - 7%. Driven by the combination of Plasma strength and the stabilization/return to growth in Interventional Technologies.
Accelerating. Raised from previous guidance of 3% - 6%. This strips out currency impacts and the strategic exit of certain liquid solution products.
Stable. The company maintained this full-year target despite suffering a 70 bps contraction in Q1. Achieving this guidance will require significant gross margin acceleration and OpEx leverage in quarters 2 through 4.
Stable. Defined as free cash flow divided by adjusted net income. Reaffirmed from prior guidance.
Key Questions
Margin Recovery Bridge
Given the 70 basis point contraction in adjusted operating margin in Q1, what are the specific levers you will pull in the next three quarters to achieve the reaffirmed full-year guidance of 50 to 100 basis points of expansion?
IVT Growth Durability
Interventional Technologies successfully returned to growth this quarter. Can you separate how much of this +2.5% growth was driven by base market procedure recovery versus share reclamation and the initial launch phase of VASCADE MVP XL?
Software Revenue Comps
You noted that upfront revenue recognition from a long-term software agreement in the prior year pressured gross margins this quarter. Are there additional lumpy software comps we should be modeling for the remainder of FY27?
Freight and Tariff Impacts
Higher freight costs were cited as an OpEx headwind. How is the 15% proactive tariff assumption you discussed in Q4 FY26 tracking, and are freight costs exceeding those initial internal expectations?